What Is CJC-1295 (No DAC)? Mechanism and Preclinical Research Summary

At a glance: CJC-1295 (No DAC) summary

CJC-1295 (No DAC) is a 29-amino acid synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). In animal models and in vitro systems, it selectively binds to the GHRH receptor on pituitary somatotropes to stimulate pulsatile secretion of growth hormone (GH) and subsequent downstream production of insulin-like growth factor 1 (IGF-1).

Unlike its drug-affinity-complex (DAC) variant, CJC-1295 (No DAC) lacks the covalent albumin-binding linker. This gives it a significantly shorter plasma half-life (roughly 30 minutes), allowing investigators to closely mimic natural, physiological endocrine pulses without causing continuous, baseline GH elevation.

Primary research areas include cellular tissue repair, extracellular matrix turnover, skeletal muscle protein synthesis, and metabolic regulation. Laboratory teams sourcing CJC-1295 (No DAC) for research must verify sequence identity via mass spectrometry and confirm purity standards exceeding 99% via High-Performance Liquid Chromatography (HPLC).

What is CJC-1295 (No DAC)? Molecular identity and structure

To understand what CJC-1295 (no DAC) is, researchers must examine the structural biochemistry of growth hormone secretagogues. The human GHRH peptide naturally consists of 44 amino acids, but preclinical studies established that the first 29 amino acids retain full biological activity. This core fragment is designated as GRF 1-29 (sermorelin). However, native GRF 1-29 is rapidly degraded in systemic circulation by endopeptidases, resulting in an in vivo half-life of less than ten minutes.

To enhance metabolic stability while retaining physiological receptor affinity, bio-chemists modified GRF 1-29 at four critical amino acid positions: Alanine at position 2 was replaced with D-Alanine, Glutamine at position 8 with Glutamic Acid, Alanine at position 15 with Glycine, and Asparagine at position 27 with Lysine. The resulting tetrasubstituted peptide—termed Modified GRF 1-29 or CJC-1295 (No DAC)—exhibits resistance to enzymatic cleavage while maintaining selective agonism at the GHRH receptor.

Because it omits the Drug Affinity Complex (a maleimidopropionic acid reactive group that binds serum albumin), CJC-1295 (No DAC) clears rapidly compared to DAC-bearing formulations. For researchers seeking precise control over exposure timing and pulsatile endocrine response, this non-conjugated analog serves as a standard control reagent. Additional technical parameters and sequence breakdowns are documented in our CJC-1295 (No DAC) research guide.

How does CJC-1295 (No DAC) act at the cellular level?

The primary mechanism of action for CJC-1295 (No DAC) centers on its selective binding to the GHRH receptor (GHRHR), a G-protein-coupled receptor located on the anterior pituitary gland's somatotrophic cells. Upon ligand binding, the receptor triggers the activation of adenylate cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) levels. This cascade activates protein kinase A (PKA), which promotes calcium influx and stimulates the transcription and exocytosis of stored growth hormone vesicles.

Once endogenous GH is released into the systemic circulation, it acts on hepatic GH receptors to stimulate the transcription and secretion of insulin-like growth factor 1 (IGF-1). IGF-1 serves as the primary mediator for cellular proliferation, protein translation, and tissue remodeling in target tissues, including skeletal muscle, articular cartilage, and dermal fibroblasts.

Preclinical data indicate that CJC-1295 (No DAC) does not significantly disrupt negative feedback loops or alter thyroid, adrenal, or prolactin axes when evaluated in controlled animal models. Its rapid clearance profile prevents receptor downregulation, preserving physiological responsiveness during multi-week experimental protocols.

What is the difference between CJC-1295 with DAC and No DAC?

The critical distinction between CJC-1295 with DAC and CJC-1295 (No DAC) lies in the presence of the Drug Affinity Complex moiety. In the DAC formulation, a maleimidopropionic acid linker is covalently bound to the C-terminus of the peptide, enabling it to form a stable bond with circulating albumin in vivo. This extends the half-life from tens of minutes to approximately 6 to 8 days, generating continuous baseline elevation of GH and IGF-1.

In contrast, CJC-1295 (No DAC) contains no albumin linker. Its half-life remains around 30 minutes, producing discrete biological spikes in growth hormone following administration. Investigators choose between these two variants based on the specific physiological questions under study:

1. Pulsatile dynamics vs. sustained elevation: Projects analyzing natural endocrine rhythms, circadian recovery, or acute tissue response utilize CJC-1295 (No DAC). Projects investigating chronic anabolic exposure or sustained IGF-1 elevation utilize the DAC variant. 2. Pituitary desensitization risk: Continuous GHRH receptor activation from long-acting analogs may lead to receptor internalization over extended timelines. Short-acting analogs permit receptor recovery between pulses. 3. Protocol precision: Short-acting compounds allow investigators to terminate signal exposure rapidly if experimental parameters require strict temporal boundaries.

You can explore the full catalog of GHRH and secretagogue variants in the PX1 Research peptide catalog.

Preclinical research models and investigative applications

In cell culture and animal models, CJC-1295 (No DAC) is primarily studied as a driver of endogenous GH and IGF-1 secretion for tissue repair research. Key areas of preclinical focus include:

Extracellular Matrix and Musculoskeletal Repair: In vitro studies on tendon-derived stem cells and dermal fibroblasts demonstrate that elevated local IGF-1 levels enhance type I collagen synthesis and accelerate extracellular matrix reorganization following mechanical injury. Rodent models receiving GHRH analogs display increased rate of force development and accelerated structural recovery in transected Achilles tendon protocols.

Skeletal Muscle Anabolism: Research models assessing protein synthesis rates indicate that systemic GH pulses upregulate myoblast differentiation via the Akt/mTOR signaling pathway. This contributes to increased nitrogen retention and reduced protein degradation during catabolic stress models.

Cardioprotective and Vascular Studies: Preclinical models exploring ischemia-reperfusion injury show that GHRH receptor stimulation exerts direct cardioprotective effects independent of systemic GH release, mitigating cell apoptosis and supporting endothelial function.

Metabolic Homeostasis: Animal models of metabolic dysfunction exhibit accelerated lipid oxidation and enhanced insulin sensitivity when exposed to pulsatile GHRH stimulation, demonstrating its utility in studying nutrient partitioning mechanisms.

Complementary research peptides: Synergistic secretagogue combinations

In secretagogue research, investigators frequently evaluate CJC-1295 (No DAC) alongside growth hormone secretagogue receptor (GHSR) agonists, commonly known as ghrelin mimetics. While GHRH analogs act on the GHRHR to amplify pulse magnitude, GHSR agonists act on a distinct pathway to increase pulse frequency and suppress somatostatin (the inhibitory hormone that halts GH release).

When CJC-1295 (No DAC) is co-administered in animal models with compounds like Ipamorelin, the combined activation of both pathways yields a synergistic release of endogenous GH that significantly exceeds the additive total of either compound administered in isolation. Other complementary research reagents evaluated in these dual-pathway protocols include GHRP-2, GHRP-6, and Hexarelin.

Researchers conducting multi-agent studies can review synthesis standards and lot compatibility across our full lineup in the PX1 Research library.

Supplier evaluation criteria: Comparing peptide vendors

Acquiring high-purity peptides for quantitative research requires strict vendor screening. Small structural impurities, residual TFA, or bacterial endotoxins can corrupt cell assays and distort binding kinetic data. The matrix below outlines the verification metrics researchers should require when selecting a vendor:

Purity Verification: Vendor must provide lot-specific High-Performance Liquid Chromatography (HPLC) chromatograms demonstrating ≥98% purity. PX1 Research tests every batch to guarantee purity standards exceeding 99%. Identity Confirmation: Vendor must provide electrospray ionization mass spectrometry (ESI-MS) reports confirming exact molecular mass matching the theoretical sequence (3367.97 g/mol). Biological Safety: Vendor must perform quantitative Chromogenic LAL testing to verify endotoxin levels are under 0.05 EU/mg, preventing inflammatory interference in cell models. Sourcing & Synthesis: Vendor must utilize domestic, USA-based solid-phase peptide synthesis (SPPS) rather than unverified overseas bulk imports. Lot Traceability: Every vial must feature an individual lot number linked directly to a public COA database. Logistics & Support: Fulfillment must occur from domestic facilities with temperature control and same-day dispatch options.

Red flags when sourcing research peptides online

The online peptide marketplace contains numerous suppliers operating without rigorous quality controls. Researchers evaluating new suppliers should watch for these critical red flags:

Generic or Reused COAs: Redact-heavy or outdated Certificate of Analysis documents that lack matching batch numbers are a primary indicator of batch reselling or unverified overseas sourcing.

Absence of Endotoxin Data: Vendors that provide HPLC data without accompanying endotoxin testing leave labs vulnerable to lipopolysaccharide (LPS) contamination, which triggers non-specific inflammatory responses in cell culture.

Human Dosing Recommendations or Medical Claims: Any vendor presenting peptides for human therapeutic use, providing medical dosages, or marketing products outside strict 'Laboratory Research Use Only' designations violates regulatory frameworks and compromises product legitimacy.

Vague Chemical Identification: Products sold without explicit sequence specifications, CAS numbers, or molecular weight documentation often hide impure peptide mixtures or improper salt forms.

Storage, handling, and reconstitution protocols for lab research

To preserve peptide integrity and prevent degradation during preclinical trials, laboratory personnel should adhere to standardized handling protocols:

Lyophilized Storage: Lyophilized CJC-1295 (No DAC) powder should be stored at -20°C for short-term projects or -80°C for long-term storage. Under these desiccated, sub-zero conditions, the peptide matrix remains stable for up to 24 months.

Reconstitution Procedures: Allow the vial to equilibrate to room temperature before reconstitution to prevent moisture condensation. Reconstitute using bacteriostatic water or sterile standard saline, directing the diluent down the glass vial wall rather than directly onto the cake to prevent agitation degradation.

Reconstituted Stability: Once reconstituted, liquid solutions should be stored at 2°C to 8°C and used within 30 days. Avoid repeated freeze-thaw cycles, as physical shear stress breaks peptide bonds and accelerates aggregation.

To order validated reagents for your laboratory, visit the official CJC-1295 (No DAC) product page.

Ordering CJC-1295 (No DAC) from PX1 Research

PX1 Research is dedicated to providing USA-synthesized, highly purified research peptides to academic institutions, biotechnology firms, and independent research facilities. When you source order 2 mg or 5 mg vials of CJC-1295 (No DAC) from our catalog, your shipment includes:

1. Lyophilized peptide vials vacuum-sealed in climate-controlled packaging. 2. Access to lot-specific third-party HPLC, MS, and endotoxin COAs downloadable directly from our portal. 3. Fast domestic transit with same-day dispatch for orders placed before 3:00 PM EST (M–F) from our California and Arizona fulfillment hubs. 4. Responsive institutional customer support handled directly by analytical specialists.

For bulk inquiries, custom synthesis, or institutional purchasing orders, explore our wholesale research program or browse our entire online store at PX1 Research.